Viatris (HAM:VIA) Beginning Cash Position: €1,166 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:VIA Viatris Inc HAM:VIA
60 GF Score
Price €15.16
GF Value €9.69
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Viatris Beginning Cash Position?

Viatris HAM:VIA +1.74% 60 Beginning Cash Position is €1,166 Mil as of Mar. 2026. GuruFocus rates HAM:VIA with a GF Score™ of 60/100 and a GF Value™ of €9.69 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Viatris's Beginning Cash Position for the quarter that ended in Mar. 2026 was €1,166 Mil.

Viatris's quarterly Beginning Cash Position increased from Sep. 2025 (€484 Mil) to Dec. 2025 (€857 Mil) and increased from Dec. 2025 (€857 Mil) to Mar. 2026 (€1,166 Mil).

Viatris's annual Beginning Cash Position declined from Dec. 2023 (€1,158 Mil) to Dec. 2024 (€949 Mil) and declined from Dec. 2024 (€949 Mil) to Dec. 2025 (€629 Mil).


Viatris Beginning Cash Position Related Terms


Viatris Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Viatris's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Beginning Cash Position Chart

Viatris Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 752.25 666.65 1,157.71 948.89 628.63

Viatris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 680.89 655.71 483.77 856.99 1,166.02
HAM:VIA
60GF Score
Viatris Inc HAM:VIA
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viatris Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €1,166 Mil mean?
Viatris (HAM:VIA) has a Beginning Cash Position of €1,166 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Viatris and its competitors.
Is Viatris' Beginning Cash Position too high?
Viatris' current Beginning Cash Position is €1,166 Mil. Overall, Viatris has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' Beginning Cash Position compare to NBIX and UTHR?
Viatris' Beginning Cash Position of €1,166 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Viatris and its competitors. Viatris's current Beginning Cash Position is €1,166 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.69, compared to a current price of €15.16 — trading 56.5% above its estimated fair value. The current Beginning Cash Position is €1,166 Mil. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Viatris (HAM:VIA), the current Beginning Cash Position is €1,166 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viatris (HAM:VIA) Overvalued in 2026?

Based on GuruFocus' analysis, Viatris stock appears to be overvalued. The current stock price of €15.16 is trading 56.5% above its estimated GF Value™ of €9.69. GuruFocus considers Viatris to be Significantly Overvalued.

Key valuation signals for HAM:VIA:

  • Beginning Cash Position: €1,166 Mil
  • GF Value™: €9.69 vs. price of €15.16 (56.5% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viatris Business Description

Address 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score

Get the complete analysis for HAM:VIA

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.16
Price
€9.69
GF Value